Investigating a new treatment for aggressive breast cancer
Official title: Ribonucleotide Reductase as a Driver of Breast Cancer Aggressiveness
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11172398 · Data updated 2026-11-12
This study is looking at a new treatment called TMU27a that targets a specific enzyme in aggressive breast cancer to help slow down tumor growth and reduce side effects compared to current therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $49,248 |
| NIH project number | 5F31CA284668-02 |
| Project ID | NIH-11172398 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced or aggressive breast cancer who have limited treatment options.
✕Less likely to help
Patients with early-stage breast cancer or those who do not have a diagnosis of breast cancer may not benefit from this research.
What this research studies
This research focuses on the role of ribonucleotide reductase (RNR) in the progression of aggressive breast cancer. It aims to develop a novel, non-nucleoside inhibitor called TMU27a, which targets RNR to induce DNA damage in cancer cells without the severe side effects associated with existing treatments like gemcitabine. By testing this new inhibitor in various human and mouse breast cancer cell lines, the research seeks to understand its effectiveness in slowing tumor growth and improving patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with advanced breast cancer that minimizes harmful side effects.
How similar studies have gone: Previous research has shown promise in targeting RNR for cancer treatment, but the specific approach of using TMU27a is novel and untested.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Brzozowski, Taylor Lynn — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Brzozowski, Taylor Lynn
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.